High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)
The purpose of this Funding Opportunity Announcement (FOA) is to support high priority research at the intersection of HIV and substance use. This FOA invites innovative research projects with the potential to open new areas of HIV/AIDS research and/or lead to new avenues for prevention, treatment and cure of HIV among people who use drugs (PWUD). Applications submitted under this FOA are required to have a detailed research plan, preliminary data, and a clear description of the nexus with substance use. This FOA is open to both individual researchers and research teams and includes all areas of research from basic science to clinical and implementation research. All studies must focus on NIH HIV/AIDS Research Priorities: NOT-OD-20-018: UPDATE: NIH HIV/AIDS Research Priorities and Guidelines for Determining HIV/AIDS Funding.
Last confirmed Oct 13, 2026 · Grants.gov
High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional): Eligibility, Deadline, and Award Questions
Who is eligible for High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)?
High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional) eligibility includes eligible applicants named in the notice. Geographic eligibility is national or notice-specific geography; applicants should confirm the source notice before applying.
What is the deadline for High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)?
High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional) has a listed deadline of March 5, 2027. Grant deadlines can change, so verify the current date with National Institutes of Health before submitting.
How much funding is available for High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)?
High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional) lists an award size of not disclosed. Award ranges and total program funding are reported from the source metadata when available.
Who funds High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)?
High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional) is funded by National Institutes of Health. GrantSonar tracks the notice with source ID 351847 from grants_gov.
Eligibility facets
Not listed in source metadata.
Not restricted in source metadata, or listed in the full notice.
Not disclosed in source metadata.
Grants.gov · 351847
Check whether this grant fits your organization
GrantSonar compares the notice against your mission, geography, eligibility, and programs before you spend time writing.